肺癌是全球高死亡率的腫瘤之一，該腫瘤侵襲轉移能力強，治療難度大，預后效果差，嚴重影響患者身心健康。血管生成是肺癌生長轉移的主要途徑之一，血管生成相關因子的分泌刺激內皮細胞參與血管生成的出芽、延伸以及管腔成熟的各個階段。中藥被廣泛應用于肺癌的現(xiàn)代藥理研究中，抑制腫瘤微環(huán)境中血管生成因子的表達，阻斷關鍵通路，延緩肺癌進展中異常血管網絡生成。綜述多種中藥通過調節(jié)內皮細胞中缺氧誘導因子-1α（HIF-1α）、血管內皮生長因子（VEGF）、成纖維細胞生長因子（bFGF）、血小板源性生長因子（PDGF）、基質金屬蛋白酶（MMPs）、血管生成素（Ang）以及細胞因子的表達，調控血管生成過程相關信號通路VEGFA/VEGFR2、PI3K/AKT、MEK/ERK、JAK2/STAT3和DLL4/Notch1，具有抑制血管內皮增殖遷移成管的藥理作用和作用機制，從而為抗肺癌血管生成藥物的研發(fā)提供新的方法和思路。

Lung cancer is among the cancers with the highest fatality rates globally. The tumor exhibits significant invasive and metastatic capabilities, poses treatment challenges, and has a grim prognosis, severely impacting patients' physical and mental well-being. Angiogenesis is a primary mechanism for the proliferation and spread of lung cancer. The release of angiogenesis-related factors activates endothelial cells to engage in the processes of sprouting, elongation, and lumen maturation during angiogenesis. Traditional Chinese medicine is extensively utilized in contemporary pharmacological research on lung cancer, suppressing the production of angiogenic factors within the tumor microenvironment, obstructing critical pathways, and postponing the development of aberrant vascular networks throughout the course of lung cancer. This article examines the impact of various traditional Chinese medicines on the expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), matrix metalloproteinases (MMPs), angiopoietin (Ang), and cytokines in endothelial cells, while also regulating the angiogenesis-related signaling pathways VEGFA/VEGFR2, PI3K/Akt, MEK/ERK, JAK2/STAT3, and DLL4/Notch1. It possesses the pharmacological action and mechanism of obstructing the proliferation and migration of vascular endothelial cells into tubular structures, thereby offering a novel approach and mechanism for the advancement of anti-lung cancer angiogenesis therapeutics.

R979.1

國家自然科學基金資助項目（82074088）； 山東省中醫(yī)藥科技項目（M-2022146）